Merck & Co. stock at USD 148.69 on September 28, 2026
Published on 09/28/2026 at 20:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co. stock last traded at USD 148.69 on the NYSE at 6:33:40 p.m. UTC on September 28, 2026, down 0.06 percent from the previous close.
Trading session
The latest regular-session quote was recorded while the market was open. The stock’s daily change was a decline of 0.06 percent.
License agreement announced
On September 28, 2026, Merck & Co., Inc. and SciBrunch Therapeutics announced an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D inhibitor, according to Business Wire.
Earlier application withdrawal
On September 25, 2026, Merck and Daiichi Sankyo voluntarily withdrew a U.S. biologics license application seeking accelerated approval for ifinatamab deruxtecan in certain previously treated patients with extensive-stage small cell lung cancer. Merck said the decision followed discussions with the U.S. Food and Drug Administration indicating that data from the IDeate-Lung01 Phase 2 trial did not satisfy requirements for the proposed accelerated approval. Enrollment continues in the IDeate-Lung02 Phase 3 trial, according to Merck.
